Healthcare reform and a desire for

This issue marks the first of a regular series of US-China Business Council (USCBC) reports analyzing key discussions and decisions of China’s bimonthly National People’s Congress (NPC) Standing Committee Meetings, the most recent of which concluded on November 4.

Hindered by redundancies in the approval process, problems securing suitable data for clinical trials, and disparities in the drug classification system between China and other countries, foreign companies have rarely found it easy to navigate China’s lengthy regulatory framework for approving pharmaceuticals and medical devices.